Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) recently announced that has completed the enrollment phase for the clinical testing of its product, Reolysin. The study will focus on patients that are afflicted with the disease colorectal cancer. The study will address advanced and metastatic stages of the disease. The study will be randomized and open with an open-label system. This is a follow up study and for that reason the drug is not mixed with placebos as the effectiveness is not in question but rather other factors important to labeling and dosages need to be determined.
103 people have been enrolled and this follows-up a six-patient safety process study. The patients will be given Flofez-6, Avastin, or Folfox-6 along with Reolysin. The study intends to determine the impact of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY)’s Reolysin drug in combination with Folfox-6. The secondary goal is to discover the toxicity and tolerance of the combination and discover the effectiveness of the treatment.
Over 132k of Americans will be found to have colorectal cancer that will result in the deaths of over 49,000 of them. The drug is also being developed to address other diseases like lung, ovarian and pancreatic cancer. Reolysin has already been given orphan drug status by the FDA for the treatment of pancreatic and ovarian cancers. Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) has also applied for orphan status addressing other cancers. The wider the scope of the drug’s effectiveness the easier it is to market to pharmacies, doctors and hospitals.
Cancer is still the number one killer in the US and any drugs that are found effective in the treatment of the disease are of extreme potential revenue value. These clinical tests are vital to the drug attaining a final clearance to be brought to market. Reolysin is a lead candidate and is close to obtaining that final clearance provided it is shown effective in these test groups. The marketplace for cancer treatment drugs is string and offering a effective treatment is important to maintain the viability of Onolytics.